Curriculum vitae del Dott. Gennaro Marotta

1974-1984: Allievo Interno presso l’Istituto di Semeiotica Medica e, dal 1980, presso l’Istituto di Medicina Interna e Malattie Dismetaboliche dell’Università degli Studi di Napoli Federico II

1984: Laurea in Medicina e Chirurgia con voti 110/110 presso l’Università degli Studi di Napoli Federico II discutendo una tesi sperimentale dal titolo:”Effetti del plasma exchange sulla circolazione arteriosa periferica in pazienti con Ipercolesterolemia Familiare”

1984: Abilitazione alla professione di Medico Chirurgo

1986-1997: Assistente Medico a tempo pieno presso l’Istituto di Medicina Interna e Malattie Dismetaboliche

1987: Specializzazione in Diabetologia e Malattie del Ricambio

1995: Specializzazione in Medicina Interna

1997: Dirigente Medico I Livello presso il Dipartimento Assistenziale di Clinica Medica

2013- 31.01.2017: Vice Direttore del Dipartimento ad Attività Integrata di Medicina Clinica

31.01.2017: Risoluzione del rapporto di lavoro con l’Università per raggiunti limiti di età

2017: Dal 1 Febbraio 2017 Conferimento di incarico triennale di Ricerca presso il dipartimento di Medicina Clinica e Chirurgia

Marzo 2018-Dicembre 2022: Collaborazione libero professionale in qualità di Dirigente Medico presso l’Istituto di Diagnosi e Cura Hermitage (reparto di Lungodegenze inizialmente e dal 1 Dicembre 2018 reparto di Riabilitazione Neurologica)

Gennaio 2023 a tutt’oggi: Collaborazione libero professionale in qualità di Primario del reparto di Lungodegenze dell’Istituto di Diagnosi e Cura Hermitage

**Principali temi di ricerca durante il lavoro all’Università:**

-Individuazione e caratterizzazione biochimica, genetica, clinica-vascolare di famiglie con: Iperlipidemia Combinata Familiare, Iper-alfa, Ipo-alfa lipoproteinemia, Ipercolesterolemia Familiare

-Valutazione di efficacia e tollerabilità di farmaci ipolipidemizzanti in studi multicentrici su pazienti afferenti all’Ambulatorio per le Dislipidemie presso il Dipartimento Assistenziale di Clinica Medica

Elenco delle più importanti pubblicazioni.

1. P. Pauciullo, P. Rubba**, G. Marotta**, C. Carbone, C. Cortese, M.G. Caruso, N. Spampinato and M. Mancini: Abnormalities in serum lipoprotein composition in patient with premature coronary heart disease compared to serum lipid matched controls: Atherosclerosis, 73:241 (1988)
2. P.Pauciullo, **G. Marotta**, P.Rubba, C. Cortese, M.G. Caruso, A.Gnasso, A. Fischetti, C. Motti and M. Mancini: Serum lipoproteins, apolipoproteins and very low density lipoproteins subfractions during six month fibrate treatment in primary hypertriglYceridemia, J. Int. Med, 228:425 (1990)
3. **G. Marotta**, P. Pauciullo and M. Mancini: Metabolic abnormalities in Hyperlipidemias, Nutrition Research, 13, Suppl. 1, 61-72 (1993)
4. A.A. Rivellese, P.Auletta, **G. Marotta**, G. Saldalamacchia, A. Giacco, V. Mastrilli, O. Vaccaro, G. Riccardi: Long term metabolic effects of two dietary methods of treating hyperlipidaemia, B.M.J., 308: 227-231 (1994)
5. V. J. Parfitt, P. Rubba, C. Bolton, **G. Marotta**, M. Hartog and M. Mancini: A comparison of antioxidant status and free radical peroxidation of plasma lipoproteins in healthy young persons from Naples and Bristol, Eur. Heart J, 15: 871-876 (1994)
6. **G. Marotta**, P. Auletta, M. Liguori, M. Turbati, G. Riccardi, O. Vaccaro: Uso della chimica a secco in una campagna per l’identificazione dei fattori di rischio per le malattie cardiovascolari, Epidemiologia & Prevenzione, 18: 230-236 (1994)
7. G.B. Vigna, P.Donega, A. Passaro, R.Zanca, L. Cattin, M.Fonda, P.Pauciullo, **G.** **Marotta**, R. Fellin, S. Gasparrini and T. Piliego: Post-prandial effects of gemfibrozil vs simvastatin in hypercholesterolemic subjects with borderline hypertriglyceridemia, Nutr Metab Cardiocasc Dis 9; 234-243, (1999)
8. P. Pauciullo, **G. Marotta**, A. Carlotto, C. Borgnino, R. Paoletti, M. Mariani and M. Mancini: Efficacy and safety of a combination of fluvastatin and bezafibrate in patients with mixed hyperlipidaemia (FACT study), XXI Congress of the European Society of Cardiology, Monduzzi Editore, 949-952 (1999)
9. [Gentile M](http://www.ncbi.nlm.nih.gov/sites/?Db=pubmed&Cmd=Search&Term=)., [Panico S](http://www.ncbi.nlm.nih.gov/sites/?Db=pubmed&Cmd=Search&Term=)., [Jossa F](http://www.ncbi.nlm.nih.gov/sites/?Db=pubmed&Cmd=Search&Term=)., [Mattiello A](http://www.ncbi.nlm.nih.gov/sites/?Db=pubmed&Cmd=Search&Term=)., [Ubaldi S](http://www.ncbi.nlm.nih.gov/sites/?Db=pubmed&Cmd=Search&Term=)., [**Marotta G**](http://www.ncbi.nlm.nih.gov/sites/?Db=pubmed&Cmd=Search&Term=)., [Pauciullo P](http://www.ncbi.nlm.nih.gov/sites/?Db=pubmed&Cmd=Search&Term=)., [Rubba P](http://www.ncbi.nlm.nih.gov/sites/?Db=pubmed&Cmd=Search&Term=). Small dense LDL particles and metabolic syndrome in a sample of middle-aged women. Findings from Progetto Atena. [*Clin Chim Acta.*](javascript:AL_get(this,%20'jour',%20'Clin%20Chim%20Acta.');) 388 pag. 179-183,  2008.
10. Pauciullo P., [Gentile M](http://www.ncbi.nlm.nih.gov/sites/?Db=pubmed&Cmd=Search&Term=)., Marotta G., Baiano A., Ubaldi S., Jossa F.,  Iannuzzo G., Faccenda F., Panico S., Rubba P. Tumor necrosis factor-α is a marker of familial combined hyperlipidemia, independently of metabolic syndrome. *Metabolism* 57 pag. 563-568, 2008.
11. Pauciullo P., [Gentile M](http://www.ncbi.nlm.nih.gov/sites/?Db=pubmed&Cmd=Search&Term=)., **Marotta G**., Baiano A., Ubaldi S., Jossa F.,  Iannuzzo G., Faccenda F., Panico S., Rubba P.: Small dense low-density lipoprotein in familial combined hyperlipidemia: Independent of metabolic syndrome and related to history of cardiovascular events. *Atherosclerosis* 203 pag. 320-24, 2009
12. Rubba P., **Marotta G**., [Gentile M](http://www.ncbi.nlm.nih.gov/sites/?Db=pubmed&Cmd=Search&Term=). [Efficacy and safety of rosuvastatin in the management of dyslipidemia.](http://www.ncbi.nlm.nih.gov/pubmed/19436657?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum) Vasc Health Risk Manag. 5 pag. 343-52, 2009.
13. [Romano M](http://www.ncbi.nlm.nih.gov/pubmed?term=)., [Di Taranto MD](http://www.ncbi.nlm.nih.gov/pubmed?term=)., [D'Agostino MN](http://www.ncbi.nlm.nih.gov/pubmed?term=)., [**Marotta G**](http://www.ncbi.nlm.nih.gov/pubmed?term=)., [Gentile M](http://www.ncbi.nlm.nih.gov/pubmed?term=)., [Abate G](http://www.ncbi.nlm.nih.gov/pubmed?term=)., [Mirabelli P](http://www.ncbi.nlm.nih.gov/pubmed?term=)., [Di Noto R](http://www.ncbi.nlm.nih.gov/pubmed?term=)., [Del Vecchio L](http://www.ncbi.nlm.nih.gov/pubmed?term=)., [Rubba P](http://www.ncbi.nlm.nih.gov/pubmed?term=).,[Fortunato G](http://www.ncbi.nlm.nih.gov/pubmed?term=). Identification and functional characterization of LDLR mutations in familial hypercholesterolemia patients from Southern Italy. [Atherosclerosis](javascript:AL_get(this,%20'jour',%20'Atherosclerosis.');) 210 pag. 493-96, 2010.
14. Gentile M, Panico S, Rubba F, Mattiello A, Chiodini P, Jossa F, **Marotta G**, Pauciullo P, Rubba P.: [Obesity, overweight, and weight gain over adult life are main determinants of elevated hs-CRP in a cohort of Mediterranean women.](http://www.ncbi.nlm.nih.gov/pubmed/20517327) Eur J Clin Nutr. 64 pag. 873–878, 2010.
15. Romano M, Di Taranto MD, Mirabelli P, D'Agostino MN, Iannuzzi A, **Marotta G**, Gentile M, Raia M, Di Noto R, Del Vecchio L, Rubba P, Fortunato G. [An improved method on stimulated T-lymphocytes to functionally characterize novel and known LDLR mutations.](http://www.ncbi.nlm.nih.gov/pubmed/21865347) J Lipid Res. 2011 Aug 24. [Epub ahead of print]
16. [Staiano A](https://www.scopus.com/authid/detail.uri?authorId=7005889430&amp;eid=2-s2.0-84879316641); [di Taranto MD](https://www.scopus.com/authid/detail.uri?authorId=16304024300&amp;eid=2-s2.0-84879316641); [Bloise E](https://www.scopus.com/authid/detail.uri?authorId=55772383300&amp;eid=2-s2.0-84879316641); [D'Agostino MN](https://www.scopus.com/authid/detail.uri?authorId=23472419200&amp;eid=2-s2.0-84879316641); [D'Angelo A](https://www.scopus.com/authid/detail.uri?authorId=55682654513&amp;eid=2-s2.0-84879316641); [**Marotta, G**](https://www.scopus.com/authid/detail.uri?authorId=7005943638&amp;eid=2-s2.0-84879316641); [Gentile M](https://www.scopus.com/authid/detail.uri?authorId=7101638352&amp;eid=2-s2.0-84879316641);[Jossa F](https://www.scopus.com/authid/detail.uri?authorId=6701768613&amp;eid=2-s2.0-84879316641); [Iannuzzi A](https://www.scopus.com/authid/detail.uri?authorId=56276904500&amp;eid=2-s2.0-84879316641); [Rubba P](https://www.scopus.com/authid/detail.uri?authorId=7006211983&amp;eid=2-s2.0-84879316641); [Fortunato G](https://www.scopus.com/authid/detail.uri?authorId=7005570713&amp;eid=2-s2.0-84879316641). Investigation of Single Nucleotide Polymorphisms Associated to Familial Combined Hyperlipidemia with Random Forests. In B Apolloni et al. (Eds.) Neural Nets and Surroundings.  [*Smart Innovation, Systems and Technologies*](https://www.scopus.com/source/sourceInfo.uri?sourceId=21100204111&origin=resultslist)*.*  19 pag. 169-178, 2013.
17. [Gentile M](http://www.ncbi.nlm.nih.gov/pubmed?term=Gentile%20M%5BAuthor%5D&cauthor=true&cauthor_uid=23994569); [Panico S](http://www.ncbi.nlm.nih.gov/pubmed?term=Panico%20S%5BAuthor%5D&cauthor=true&cauthor_uid=23994569); [Mattiello A](http://www.ncbi.nlm.nih.gov/pubmed?term=Mattiello%20A%5BAuthor%5D&cauthor=true&cauthor_uid=23994569); de Michele M, Iannuzzi A; Jossa F; **Marotta G**; Rubba P. Plasma Creatinine levels, estimated Glomerular Filtration Rate and Carotid Intima Media Thickness in middle-aged women: a population based cohort study. *Nutr Metab Cardiovasc Dis* 24 pag. 677-680, 2014.
18. Ruotolo A., Di Taranto MD.; D’Agostino MN[;](http://www.degruyter.com/view/j/cclm-ahead-of-print/cclm-2014-0144/cclm-2014-0144.xml#aff2) **Marotta G**;  Gentile M;   Nunziata M; Sodano M;  Di Noto R; Del Vecchio L; Rubba P; [Fortunato](mailto:fortunat@unina.it) G. The novel variant p.Ser465Leu in the *PCSK9* gene does not account for the decreased LDLR activity in members of a FH family. *Clin Chem Lab Med* 52 pag.175-8, 2014.
19. Di Taranto MD; Staiano A; D'Agostino MN; D'Angelo A; Bloise E; Morgante A; **Marotta G**; Gentile M; Rubba P; Fortunato G; [Association of USF1 and APOA5 polymorphisms with Familial Combined Hyperlipidemia in an Italian population.](http://www.ncbi.nlm.nih.gov/pubmed/25308402) *Mol Cell Probes*  29 pag 19-24, 2015.
20. Gentile M; Calcaterra I; Strazzullo A; Pagano C; Pacioni D; Speranza E; Rubba P; **Marotta G.** Effects of Armolipid Plus on small dense LDL particles in sample of patients affected by Familial Combined Hyperlipidemia. *Clinical Lipidology* 10 pag. 475-480,  2015.
21. Gentile M; Iannuzzo G;  Mattiello A; **Marotta G**; Iannuzzi A; Panico S; Rubba P. Association between Lp (a) and atherosclerosis in menopausal women without Metabolic Syndrome.  *Biomarkers in Medicine*  10  Pag. 397-402, 2016.
22. [Di Taranto MD](http://www.ncbi.nlm.nih.gov/pubmed/?term=Di%20Taranto%20MD%5BAuthor%5D&cauthor=true&cauthor_uid=27225395); [Gelzo M](http://www.ncbi.nlm.nih.gov/pubmed/?term=Gelzo%20M%5BAuthor%5D&cauthor=true&cauthor_uid=27225395); [Giacobbe C](http://www.ncbi.nlm.nih.gov/pubmed/?term=Giacobbe%20C%5BAuthor%5D&cauthor=true&cauthor_uid=27225395);[Gentile M](http://www.ncbi.nlm.nih.gov/pubmed/?term=Gentile%20M%5BAuthor%5D&cauthor=true&cauthor_uid=27225395); [**Marotta G**](http://www.ncbi.nlm.nih.gov/pubmed/?term=Marotta%20G%5BAuthor%5D&cauthor=true&cauthor_uid=27225395); [Savastano S](http://www.ncbi.nlm.nih.gov/pubmed/?term=Savastano%20S%5BAuthor%5D&cauthor=true&cauthor_uid=27225395); [Dello Russo A](http://www.ncbi.nlm.nih.gov/pubmed/?term=Dello%20Russo%20A%5BAuthor%5D&cauthor=true&cauthor_uid=27225395); [Fortunato G](http://www.ncbi.nlm.nih.gov/pubmed/?term=Fortunato%20G%5BAuthor%5D&cauthor=true&cauthor_uid=27225395); [Corso G](http://www.ncbi.nlm.nih.gov/pubmed/?term=Corso%20G%5BAuthor%5D&cauthor=true&cauthor_uid=27225395). Cerebrotendinous xanthomatosis, a metabolic disease with different neurological signs: two case reports. [*Metab Brain Dis.*](http://www.ncbi.nlm.nih.gov/pubmed/27225395) 31 Pag. 1185-1188, 2016

Autorizzo il trattamento dei dati personali presenti nel CV ai sensi del D. Lgs. 2018/101 e del GDPR (Regolamento UE 2016/679).

Napoli, 15 Giugno 2024